The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a week.

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an auto-injector pen.

HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

Today’s approval of Hympavzi provides patients with hemophilia a new treatment option that is the first of its kind to work by targeting a protein in the blood clotting process,” said Ann Farrell, M.D.